Maxime Sasseville

Use of patient-reported outcomes to inform symptom and functional outcomes in cancer drug regulatory decisions: challenges and future directions

Francesco Pignatti, Peter G. M. Mol, Chantal Quinten, Douwe Postmus et autres

nl, no, ca, jp, us (code pays fourni par la source)

Handling missing values in patient-reported outcome data in the presence of intercurrent events

Doranne Thomassen, Satrajit Roychoudhury, Cecilie Delphin Amdal, Dries Reynders et autres

INTRODUCTION: As patient-reported outcomes (PROs) are increasingly used in the evaluation of medical treatments, it is important that PROs are carefully analyzed and interpreted. This may be challenging due to substantial missing values. The missingness in PROs is often closely related to …

nl, us, no, be, de (code pays fourni par la source)

The role of the estimand framework in the analysis of patient-reported outcomes in single-arm trials: a case study in oncology

Doranne Thomassen, Satrajit Roychoudhury, Cecilie Delphin Amdal, Dries Reynders et autres

BACKGROUND: Patient-reported outcomes (PROs) play an increasing role in the evaluation of oncology treatments. At the same time, single-arm trials are commonly included in regulatory approval submissions. Because of the high risk of biases, results from single-arm trials require careful interpretation. This …

nl, us, no, be, de (code pays fourni par la source)

Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials – insights from an expert virtual roundtable

Anna Minchom, Melanie Calvert, Steven Rizk, Philip Collis et autres

us (code pays fourni par la source)

Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials – insights from an expert virtual roundtable

Christina Yap, Olalekan Lee Aiyegbusi, Emily Alger, Ethan Basch et autres

Early phase clinical trials provide an initial evaluation of therapies' risks and benefits to patients, including safety and tolerability, which typically relies on reporting outcomes by investigator and laboratory assessments. Use of patient-reported outcomes (PROs) to inform risks (tolerability) and benefits (improvement …

gb, us, nl, au, de, be, ca (code pays fourni par la source)

Inclusive search for squarks and gluinos in pp collisions at s=7 TeV

S. Chatrchyan, V. Khachatryan, A. M. Sirunyan, A. Tumasyan et autres

A search is performed for heavy particle pairs produced in $\sqrt{s}=7\text{ }\text{ }\mathrm{TeV}$ proton-proton collisions with $35\text{ }\text{ }{\mathrm{pb}}^{\ensuremath{-}1}$ of data collected by the CMS experiment at the LHC. The search is sensitive to squarks and gluinos of generic supersymmetry models, provided …

am, at, be (code pays fourni par la source)

Inclusive b-hadron production cross section with muons in pp collisions at $ \sqrt {s} = 7\;{\text{TeV}} $

V. Khachatryan, A. M. Sirunyan, A. Tumasyan, W. Adam et autres

am, at, by, be (code pays fourni par la source)